Phreesia (PHR) Insider Gillian Munson Buys $185K of Stock
Gillian Munson purchased 19,290 shares of Phreesia, Inc. at $9.59 each on June 24, 2026, totaling around $185,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Gillian Munson bought 19,290 shares of Phreesia, Inc. ($PHR) at an average price of $9.59, worth about $184,991.10, on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $PHR is up 11.8% after 1 week, up 6.6% after 1 month and up 14.1% to date (from the $9.59 close on Jun 24, 2026).
PHR
Phreesia, Inc.
Key Points
- Gillian Munson bought 19,290 shares of Phreesia, Inc. at a price of $9.59 each, totaling about $184,991 on June 24, 2026.
- The stock closed at $9.13 on the published date, indicating a significant purchase relative to its recent trading price.
- Phreesia, Inc. has a market cap of about $622.6 million and a P/E ratio of 55.72, reflecting its growth in the healthcare sector.
Get $PHR trade alerts by text
We text you when insiders, Congress or big funds trade $PHR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Phreesia, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Phreesia, Inc.
Gillian Munson bought 19,290 shares of Phreesia, Inc. at $9.59 each on June 24, 2026. The total value of this purchase was approximately $184,991. This trade stands out as a substantial insider move, especially considering the stock's recent closing price of $9.13.
Other Insiders Join the Purchase
Several other insiders also made identical purchases on the same day. Jon Kessler, Lisa Egbuonu-Davis, Ramin Sayar, Smith Mark Douglas, and Lainie Goldstein each acquired 19,290 shares at the same price of $9.59. Each of these trades was valued at about $184,991. This coordinated buying effort among insiders suggests a strong collective belief in the company's future potential.
Stock Performance Context
As of June 24, 2026, Phreesia, Inc. shares were trading at $9.13, which is below their 52-week high of $25.00. The stock has seen a low of $7.77 in the past year, making the recent insider purchases noteworthy as they occur at a time when the stock is trading well below its recent highs. The company has a market capitalization of approximately $622.6 million and a P/E ratio of 55.72, indicating it is valued highly relative to its earnings.
Analysts Set New Price Targets
Analysts have mixed opinions on Phreesia, Inc. On October 12, 2026, Barclays maintained an Equal-Weight rating with a price target of $11.00. DA Davidson also kept a Buy rating with a target of $13.00 on September 4, 2026. However, Raymond James downgraded the stock to Market Perform on September 8, 2026, indicating varying outlooks among analysts.
What Phreesia, Inc. Does
Phreesia, Inc. provides software and payment solutions for the healthcare industry, focusing on improving patient engagement and streamlining operations for healthcare providers. The recent insider buying reflects confidence in the company's strategy and its potential for future growth in the healthcare sector.
What's Next for Phreesia
Phreesia is set to report its next earnings on December 7, 2026. Investors will be keen to see how the company's financial performance aligns with the optimistic views expressed by its insiders. The latest insider trades reflect positions as of June 24, 2026, and may not represent current holdings, but they do indicate a significant commitment from the company's executives.
Related Filing Alerts
Source: Gillian Munson's Form 4 filing on $PHR (Jun 24, 2026). Find the original filing: PHR Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts